LP-284 will be assessed for its potential to treat mantle cell lymphoma, double hit lymphoma, high-grade B-cell lymphomas and other solid tumours in patients. Credit: Ground Picture / Shutterstock.com.

Lantern Pharma has dosed two subjects in a Phase Ia/Ib clinical trial of its investigational drug LP-284 for relapsed or refractory non-Hodgkin’s lymphoma (NHL).

A new small molecule, LP-284 has a synthetically lethal mechanism of action that kills cancer cells harbouring mutations in DNA damage repair pathways.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The multicentre, open-label trial aims to determine the safety and tolerability of varying doses of the molecule.

LP-284 will be assessed for its potential to treat mantle cell lymphoma (MCL), double hit lymphoma (DHL), high-grade B-cell lymphomas (HGBL), and selected solid tumours and sarcomas.

The trial will also investigate the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) in patients with relapsed or refractory (r/r) lymphomas and solid tumours.

See Also:

Characterising the pharmacokinetics (PK) of LP-284 and evaluating its clinical activity are the trial’s secondary objectives.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Patients in the trial will receive LP-284 intravenously on days one, eight, and 15 of a 28-day cycle.

The study is structured in two parts: a dose escalation portion to confirm MTD and/or RP2D (Phase Ia) and dose expansion (Phase Ib).

Lantern plans to enrol up to 30 subjects in Phase Ia portion with the total number depending on the number of dose levels assessed.

Phase Ib portion could enrol up to 40 subjects in each cohort for MCL and HGBL, including diffuse large B-cell lymphoma (DLBCL) tumours.

Lantern president and CEO Panna Sharma said: “Enrolling and treating initial patients in our Phase I trial for LP-284 is a major milestone and underscores the commitment of our team to advancing our pipeline of AI-driven therapies to patients.

“We believe LP-284 has unique and breakthrough potential for patients with relapsed or refractory lymphomas and certain solid tumours with certain genomic signatures, many of which have no or limited effective therapeutic options.”

“Insights from our proprietary AI and ML platform, RADR, were instrumental in our development of LP-284 and aided in understanding its mechanism of action, identifying and prioritising its cancer indications, and generating machine learning biomarker signatures to assist with patient selection in future clinical trials.”